Polen High Income ETF (PCHI)

In our clinical risk reviews, we emphasize looking closely at how actively managed funds handle credit quality during macro shifts. When evaluating PCHI with managers like John Sherman, Ben Santonelli, and David Breazzano at the helm, the focus shifts to whether their risk-controlled framework can genuinely insulate against issuer-level dispersion in the leveraged loan market.

On our desk, the narrative around PCHI is all about capturing the persistent yield and spread advantage as the Federal Reserve implements rate cuts. However, traders are heavily split because while the fundamental yield story looks attractive, the macro trend shows the fund trading beneath its 20-day, 50-day, and 200-day moving averages.

Watching the 50-day EMA cross below the 200 SMA on PCHI tells me we are dealing with a clear technical Death Cross. Even though the product is designed for high income and long-term capital growth within the high-yield bond asset class, the current composite technical score sits at a heavy 'Strong Sell' (-0.73), demanding caution.

From a quantitative perspective, PCHI's RSI reading of 47.1 suggests subdued momentum without hitting oversold territory. Coupled with a MACD below zero and a negative histogram, our quantitative models flag a persistent bearish alignment that overrides the immediate dividend and income allure.

As a risk manager reviewing the FundVantage Trust prospectus for PCHI, I have to highlight the structural ETF risks mentioned by Polen Capital—specifically that shares may trade at a premium or discount to net asset value, or that secondary trading markets could experience liquidity disruptions.